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Available online 23 December 2016Background:Meta-analyses of cardiac rehabilitation trials up to 2010 showed a signiﬁcant reduction in all-cause
mortality butmanyof these trialswere conducted before themodernmanagement of acute coronary syndromes.
Methods:We undertook a meta-analysis of contemporary randomised controlled trials published in the period
2010 to 2015, including patientswith other forms of atherosclerotic cardiovascular disease, to investigate the im-
pact of cardiovascular prevention and rehabilitation on hard outcomes including survival.
Results: 18 trials randomising 7691 patients to cardiovascular prevention and rehabilitation or usual care were
selected. All-cause mortality was not reduced (RR 1.00, 95% CI 0.88 to 1.14), but cardiovascular mortality was
by 58% (95% CI 0.21, 0.88).Myocardial infarctionwas also reduced by 30% (95%CI 0.54, 0.91) and cerebrovascular
events by 60% (95% CI 0.22, 0.74). Comprehensive programmes managing six or more risk factors reduced all-
cause mortality in a subgroup analysis (RR 0.63, 95% CI 0.43, 0.93) but those managing less did not. In the
three programmes that prescribed and monitored cardioprotective medications for blood pressure and lipids
all-cause mortality was also reduced (RR 0.35, 95% CI 0.18, 0.70).
Conclusions: Comprehensive prevention and rehabilitation programmes managing six or more risk factors, and
those prescribing and monitoring medications within programmes to lower blood pressure and lipids, continue
to reduce all-cause mortality. In addition, these comprehensive programmes not only reduced cardiovascular
mortality and myocardial infarction but also, for the ﬁrst time, cerebrovascular events, and all these outcomes
across a broader spectrum of patients with atherosclerotic disease.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cardiovascular prevention1. Introduction
Coronary heart disease and cerebrovascular disease constitute the
most important preventable non-communicable diseases, in which
cardiac rehabilitation plays an important role [1]. It is deﬁned by the
WHO as: ‘the sum of activities required to inﬂuence favourably the
underlying cause of the disease, as well as the best possible, physical,
mental and social conditions, so that they (people) may, by their own
efforts preserve or resume when lost, as normal a place as possible in
the community. Rehabilitation cannot be regarded as an isolated form
or stage of therapy butmust be integrated within secondary prevention
services of which it forms only one facet’ [2].
Cardiac rehabilitation programmes in the past reduced all-cause
mortality. In the 2011 Cochrane review of exercise-based rehabilitationeliability and freedom from bias
dation (NHS 2015-2).
epartment of Cardiology, Room
nds.
n Domburg).
land Ltd. This is an open access articlby Heran et al. [3], total mortality was reduced by 18% during follow-up
of 6 up to 12 months, and by 13% during follow-up of over one year,
while cardiovascular mortality was reduced by 26%. Results of lifestyle
modiﬁcation programmes are similar. In 2012, Janssen et al. reported
a signiﬁcant reduction of a third in total mortality, while cardiacmortal-
ity was halved signiﬁcantly, for lifestyle modiﬁcation programmes [4].
Both Heran and Janssen included trials that contained both exercise-
based rehabilitation and lifestyle modiﬁcation. The effect of ‘education
only programmes’ by Cochrane one year later, showed no evidence of
a signiﬁcant reduction in all-cause mortality (RR 0.79, 95% CI 0.55 to
1.13), or recurrent MI, revascularisation and hospitalisation [5]. This
may have been due to lack of statistical power, as few studies reported
on these outcomes and few events occurred. In addition, psychological
interventions did not reduce total mortality or non-fatal events in an-
other Cochrane meta-analysis [6]. Of course, such programmes may
still improve psychological outcomes which are important [6].
International guidelines strongly (Class I) recommend cardiac reha-
bilitation for all patients following cardiac surgery or a myocardial in-
farction [7–11]. However, in clinical practice uptake is low at 36.5% in
EUROASPIRE III across 22 countries for patients with a myocardial in-
farction (MI), percutaneous coronary intervention or coronary arterye under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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of rehabilitation programmes between countries [12].
The acute management of cardiovascular disease, both acute coro-
nary syndromes and stroke, has been transformed by percutaneous
revascularisation, stenting, thrombolysis and cardioprotective medica-
tions reducing all-cause mortality and subsequent cardiovascular
events. Against this background, we evaluated the added value of car-
diovascular prevention and rehabilitation programmes published in
the last ﬁve years. We broadened the scope of our analysis beyond car-
diac patients by including studies of patients with other manifestations
of atherosclerotic cardiovascular disease. As future cardiovascular risk is
strongly related to blood pressure and lipids levels, we also assessed
whether management of these risk factors within prevention and reha-
bilitation programmes is of value.
2. Methods
The search strategy, study selection, data extraction and analysis all
took place according to a pre-deﬁned protocol, details of which are de-
scribed below. We conducted and reported this meta-analysis in accor-
dance with the PRISMA (Preferred Reporting Items for Systematic
Reviews andMeta-Analyses) statement [2] and the CochraneHandbook
for Interventional Reviews [13].
2.1. Search strategy
One author (G. H.) systematically searched Medline and Embase on
OvidSP. The basis of our search strategy was Heran's Cochrane analysis
[3] on exercise based programmes for cardiac rehabilitation. To broaden
our search to lifestyle programmes, we added Ebrahim's Cochrane [14]
search strategy on health behaviour and lifestyle programmes. The
main search terms were the following: “ischaemic heart diseases”, “ex-
ercise based rehabilitation” and “health behaviour or lifestyle pro-
gramme”. The detailed search strategy is available online in
Supplementary material. Reference lists of retrieved articles and sys-
tematic reviews andmeta-analyseswere veriﬁed to identify any studies
not detected by the electronic search. The search was done on February
27, 2015, and included studies published from January 1, 2010 to Febru-
ary 27, 2015.
2.2. Study selection
We included randomised controlled clinical trials (RCTs) of cardio-
vascular prevention and rehabilitation with a follow-up period of at
least six months, written in either English, Chinese, Spanish, German,
French or Dutch languages.
2.2.1. Patients
We included studies of patients with myocardial infarction (MI), of
patients who had undergone coronary revascularisation (coronary ar-
tery bypass grafting or percutaneous coronary intervention), or with
angina pectoris or coronary artery disease established by angiography.
In addition, we included trials of participants diagnosedwith cardiovas-
cular disease, e.g. peripheral arterial disease, ischaemic cerebrovascular
accidents, diabetes mellitus or hypertension, if over 50% of the patients
in the studies were diagnosed with coronary heart disease. Studies of
participants who had undergone heart valve surgery, heart transplanta-
tion, cardiac-resynchronisation therapy or implantable deﬁbrillator
therapy or with over 50% of patients diagnosed with heart failure,
were excluded.
2.2.2. Intervention
The intervention could be either an exercise or a lifestyle based
programme. Criteria for exercise based programmes were derived
from Heran et al. [3]. Actual physical exercise training had to be part
of the rehabilitation programme. The criteria for a lifestyle modiﬁcationprogramme were based on Janssen et al. 2012 [4]. At least one face-to-
face session between the health care provider and the patient had to
take place, and the aim of the programme had to comprise improved
diet and/or exercise habits. Of course, some rehabilitation programmes
focussed both on exercise training and on health behaviour.
2.2.3. Comparison
The intervention had to consist of a comparison with usual care.
Studies that randomised patients between standard cardiac rehabilita-
tion and standard cardiac rehabilitation followed by extended forms
of rehabilitation, were also eligible.
One investigator (G.H.) evaluated studies for possible inclusion.
Non-relevant studies were excluded based on title and abstract. For po-
tentially relevant studies, full-text was obtained and two investigators
(G.H. and H.T.) independently assessed study eligibility and extracted
the data on study design, patient characteristics, and outcomes.
Disagreement was resolved by consensus or by discussion with a third
author (K.K.).
2.2.4. Outcomes and measurements
The primary efﬁcacy outcome of our analysis was all-cause and
cardiovascular mortality. In addition, we analysed the two following –
secondary – outcomes: the occurrence of MI and of cerebrovascular
events (stroke and transient ischaemic attacks). All MI and cerebrovas-
cular events were extracted, both fatal and non-fatal. Two authors (G.H.
and H.T.) independently extracted the outcomes from all studies.
2.3. Study quality assessment
Quality of studies included was assessed using the Cochrane Risk of
Bias tool.
2.4. Data analysis
All analyses were performed on data reported according to the
intention-to-treat principle. Data from each study were pooled using
the Mantel-Haenszel method. A ﬁxed effects model was used, except
in the presence of substantial (I2 N 50%) heterogeneity, in which case a
random effects model was chosen. The effects of the interventions
were expressed as relative risk ratio's (RR).
Potential effect modiﬁers were explored by pre-speciﬁed subgroup
analyses focusing on the primary outcome of all-cause mortality. To
this end, we considered the duration of follow-up— ≤12months versus
follow-up N12 months. Furthermore, we analysed the number of risk
factors managed in the programmes: b6 versus ≥6. The risk factors
were based on the British Association of Cardiovascular Prevention
and Rehabilitation 2012 guideline and were: smoking cessation, physi-
cal exercise training, counselling for exercise/activity, diet, blood pres-
sure (control of values), cholesterol (control of serum values),
diabetes (control of glucose values), checking medication and stress
management [14]. We assessed the effect of prescription and monitor-
ing of medication within programmes as opposed to deferring the re-
sponsibility for prescribing to others outside the programmes. We also
analysed the impact of whether or not any form of standard cardiac re-
habilitationwas offered to the control group.We did a separate analysis
for blood pressure and LDL cholesterol levels, measured as a weighted
mean difference (WMD). Other subgroup analyses are included in Sup-
plementary material online.
Publication bias was assessed by inspection of the funnel plot and
Egger's test. Sensitivity analysis was conducted by removing studies
one-by-one.
ReviewManager 5.3 was used to analyse the data, to draw the plots
and to generate the ﬁgures [15]. The meta-essentials workbook for
Microsoft Excel was employed for Egger's test [16].
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3.1. Search
The search yielded 7764 titles. Seven additional studies were re-
trieved from meta-analyses, presentations or comments that were
found within our search strategy [4,5,17–21]. After reviewing the titles
and abstracts, we retrieved 71 full-text articles for possible inclusion
(Fig. 1). Eighteen of these fulﬁlled our in- and exclusion criteria and
are included in the present analyses. Details of these RCTs are given in
Table 1.3.2. Included studies
Eighteen studieswere included. Trial sample sizes ranged from 34 to
1813 patients. Overall, 7691 patients were studied. The median
intervention duration was 12 months and the median follow-up was
24 months.
The mean age of patients ranged from 56 to 70 years. All studies
included women, ranging from 16 to 30%. One study was conducted in
females only [22]. The studies by Reid et al. consisted of two separate
programmes, one internet based [23], the other one by phone counsel-
ling [24] and these were named and considered accordingly. Four stud-
ies included patients with other cardiovascular diseases than coronary
artery disease including peripheral vascular disease and ischaemic
stroke [21,25–27]. In total, 989 patients in this meta-analysis were diag-
nosed with other cardiovascular diseases.Fig. 1. Study ﬂo3.3. Risk of bias in included studies
Random sequence generation and allocation bias among the
publications was low. Blinding of patients is not possible in rehabilita-
tion programmes and was therefore not assessed. The blinding of the
researchers that analysed the data was mostly unclear. Attrition bias –
caused by incomplete outcome data –was scored as relatively high be-
cause a considerable number of trials reported N10% loss to follow-up.
Furthermore, reasons for loss to follow-up and dropout were often not
reported. On the other hand, the loss to follow-up was quite evenly dis-
tributed between both arms of studies. Selective outcome reporting
could be a risk of bias as the smaller studies were not designed to assess
treatment group differences for mortality and may not have fully re-
ported all clinical events that occurred during the follow-up period.
See Supplementary material online for an overview of risk of bias
given to each study.3.3.1. Effects of interventions
3.3.1.1. Mortality.Mortality was reported in all studies. Overall, 735 out
of 7691 patients died (Fig. 2), and the median yearly mortality rate
was 1.4%. Mortality was comparable among intervention and control
groups (RR 1.00, 95% CI 0.88, 1.13). The effect of cardiovascular preven-
tion and rehabilitation onmortality was notmodiﬁed by the duration of
the intervention programme (≤12 months (RR 0.99, 95% CI 0.73, 1.34)
versus N12months (RR 1.02, 95% CI 0.90, 1.17) (Supplementarymateri-
al online, Fig. S1).w diagram.
Table 1
Characteristics of studies.
Study n Population Country Men% Mean
Age
Intervention Control Duration of
intervention
Follow-up
Astengo (2010) 62 Stable AP + planned
for PCI
Sweden 77 63 Home-based training on bike ergometer,
70% of maximum capacity 5 days/week.
Two patients did a
standard rehabilitation
programme. Others
usual care.
8mo 8mo
Brotons (2011) 1224 ACS 60%, CVA 33%, PAD
7%
Spain 70 66 Nurse-led individual sessions at Primary
Health Centres for diet, exercise and
smoking. Monitoring of medical
treatment.
Usual care 24mo 36mo
Carrington
(2013)
602 CHD 62%, Arrhythmia
20%, HF 7%, 3% valve
disease.
Australia 72 70 Nurse-led home visits and phone
counselling. Referring 52% to cardiac
rehabilitation programme for high risk
factors and monitoring medication.
Same nurse-led intake.
Short cardiac
rehabilitation
programme.
24mo 24mo
Cohen (2014) 502 ACS France 84 66 Nurse-led smoking consultation. Dietary
and physical activity consultation.
Usual care 12mo 24mo
Haglin (2011) 48 subgroup with CHD Sweden 73 ? Multidisciplinary programme focused on
lifestyle management. In hospital
programme, workshops and home
programme.
Usual care 5 years 18.5 years
Hawkes (2013) 430 MI Australia 75 61 Goal directed telephone coaching. Same
cardiac rehabilitation participation as
control.
Educational booklet
and quarterly
newsletter.
6mo 24mo
He (2012) 263 PCI China 81 64 Behaviour change sessions on risk
factors. Telephone counselling on risk
factor control and medication.
Same behaviour
change sessions and
usual follow-up.
12mo 24mo
Janssen (2014) 210 CHD The
Netherlands
81 58 Psychologist-led programme focused on
maintenance of lifestyle change.
Motivational counselling intake followed
by group sessions and booster sessions.
Standard
comprehensive
rehabilitation
programme before
randomisation. One
psychologist's intake.
15mo 24mo
Jorstad (2013) 696 ACS The
Netherlands
80 58 Nurse-led hospital based sessions with
motivational interviewing for risk factors
and titration of medication. Standard
cardiac rehabilitation.
Standard
comprehensive cardiac
rehabilitation.
12mo 24mo
Krebs (2013) 34 ACS + hyperglycaemia New
Zealand
75 63 Nurse promoted GP consultations after
ACS for hyperglycaemic ACS patients to
prevent diabetes mellitus type 2 and
cardiac events.
Standard cardiac
rehab, half of
intervention and
control group
participated.
9mo 24mo
Moreno-Palanco
(2011)
247 ACS 65%, CVA 35% Spain 75 65 Nurse-led visits consisting of lifestyle
modiﬁcations and modiﬁcation of
medication.
Usual care with yearly
consultation.
36mo 36mo
Mosca (2010) 304 CHD USA 0 62 Nutrition and exercise counselling.
Referral to smoking cessation
programme.
2 reports for the GP
with unmet prevention
goals according to
AHA/ACC standard.
3mo 24mo
Pinto (2011) 130 MI, AP, CABG USA 79 64 Patients were randomised after standard
comprehensive cardiac rehabilitation.
Case managers called to maintain
exercise. Patients logged their exercise.
Standard cardiac
rehabiliation.
6mo 24mo
Reid (2012)
online
programme
223 ACS + PCI Canada 84 56 Online programme for patients who
didn't want to participate in a cardiac
rehab programme. A physiotherapist
made a programme. Online activity
logging, tutorials and email feedback and
contact.
Activity guidance from
their cardiologist.
5mo 24mo
Reid (2012)
phone
counselling
141 ACS + PCI Canada 73 61 Intake followed by motivational phone
counselling by a physiotherapist for
physical activity in patients who didn't
want to participate in cardiac rehab.
Activity guidance from
their cardiologist.
12mo 24mo
Safﬁ (2014) 74 ACS Brazil 74 58 Nurse-led lifestyle counselling in
individual sessions and phone contact.
2 counselling sessions
about medication and
risk factors.
15mo 24mo
Stewart (2015) 624 CVD (CHD 70%, DM
27%, PAD 17%, CVA
13%)
Australia 71 66 Nurse-led programme. Referrals to
pharmacists (9%), dietitians (13%),
additional cardiac rehabilitation (30%),
exercise programmes (12%) if needed.
Also phone ‘coaching’/home visits. If a
cardiovascular rehospitalisation
occurred, the health plan was revised.
Assessment with
report for GP and
specialists.
36mo 51mo
West (2012) 1813 MI United
Kingdom
74 65 Standard cardiac rehabilitation
programmes that were already in use
were the intervention. The programmes
followed the British guidelines. These
contained exercise training, risk factor
Patients could attend
local patient support
groups, but not cardiac
rehabilitation.
7wks 8 years
(continued on next page)
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Table 1 (continued)
Study n Population Country Men% Mean
Age
Intervention Control Duration of
intervention
Follow-up
and treatment education, and
counselling for recovery.
Coronary heart diseases (CHD)
MI Myocardial infarction
AP Angina pectoris
Description of possible CHD presentation
HF Heart failure
Cardiac treatment
PCI PTCA (Percutaneous transluminal coronary angioplasty)/PCI (percutaneous coronary intervention)/Dotter
CABG Coronary bypass graft
Other cardiovascular diseases (CVD)
CVA Cerebrovascular Accident (ischaemic)
PAD Peripheral arterial disease
DM Diabetes mellitus
A comma ‘,’ denotes several patient groups that constituted the total group. For example MI, CVA would be a group of patients that had MI or CVA. Percentages are added if the authors
presented the distribution of diagnoses.
‘+’ denotes patients that had both, for example patients with an acute coronary syndrome that underwent PCI can be written as: ACS + PCI.
Acute coronary syndrome can be used to summarise MI and UAP as a patient group: ACS = MI + UAP. CHD can be used if it exists for longer.
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four RCTs (N = 1046) (Fig. 3). Cardiovascular mortality was reduced
by cardiovascular prevention and rehabilitation (RR 0.42, 95% CI 0.21,
0.88). There was some statistical heterogeneity across trials for total
and cardiovascular mortality (I2 = 27% and I2 = 24% respectively). In
the studies that reported cardiovascular mortality, all-cause mortality
was also reduced (RR 0.53, 95% CI 0.29, 0.97).3.3.1.2. Morbidity. Four studies [20,26–28] (N = 3416) reported
events including myocardial infarction (Fig. 4) and cerebrovascular
events (Fig. 5). The total number of events amounted to 212 MI
events and 49 cerebrovascular events. The occurrence of MI was
reduced by cardiovascular prevention and rehabilitation (RR 0.70, 95%
CI 0.54, 0.91), and cerebrovascular events were also reduced (RR
0.40, 95% CI 0.22, 0.74). In the studies that reported MI and
cerebrovascular events, all-cause mortality was not reduced (RR 0.98,
95% CI 0.85, 1.13). The number needed to treat to prevent one MI was
45 and 82 for cerebrovascular events. There was no statistical
heterogeneity detected across trials for any of the morbidity outcomes
(I2 = 0% for both).Fig. 2. All-cause3.3.2. Additional analyses
3.3.2.1. Risk factors addressed. Six studies (N = 2470) addressed six or
more risk factors in their programme, and twelve studies (N = 5221)
addressed less than six risk factors (Fig. 6). The subgroup that addressed
six or more risk factors reduced the relative risk of all-cause mortality
signiﬁcantly to 0.63 (95% CI 0.43, 0.93.). Thiswas not the case for studies
that addressed less risk factors (RR 1.08 (95% CI 0.94, 1.24)). The test for
subgroup differences was signiﬁcant (p = 0.01). Heterogeneity was
moderate in the six or more risk factors subgroup (I2 = 47%) and low
in the less than six risk factors subgroup (I2 = 0%).3.3.2.2. Medication prescription. Three RCTs [27–29] (N=1035) incorpo-
rated prescription andmonitoring ofmedication as part of the interven-
tion, and 15 studies (N=6656) did not prescribemedication during the
intervention (Fig. 7). In the prescription of medication programmes, all-
cause mortality was reduced compared to control with a relative risk of
0.35 (95% CI 0.18, 0.70). In contrast, no prescription of medication did
not reduce all-cause mortality (RR 1.06 (95% CI 0.93, 1.21). The test
for subgroup differences was signiﬁcant (P = 0.002). Heterogeneitymortality.
Fig. 3. Cardiovascular mortality.
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and low in the no prescription of medication subgroup (I2 = 0%).
3.3.2.3. Type of control group. Twelve studies (N= 5108) had usual care
which did not include standard cardiac rehabilitation (Supplementary
material online, Fig. S4). In six studies (N= 2583) usual care included
standard cardiac rehabilitation. However, there was no reduction in
all-cause mortality in either group (RR 0.99, 95% CI 0.86, 1.14 and
1.07, 95% CI 0.74, 1.54 respectively).
3.3.2.4. Blood pressure. Three studies [22,26,30] reported systolic and di-
astolic blood pressure management by the percentage of patients
achieving target level. Six studies [25,27–29,31,32] (N = 2008)
analysed both mean systolic and diastolic blood pressure. Systolic
blood pressure was signiﬁcantly reduced in those studies that pre-
scribed and monitored medications within programmes (−3.16 mm
Hg 95% CI−5.55,−0.77). The programmes that did not prescribemed-
ications did not show a signiﬁcant difference (−2.71 mm Hg 95% CI
−5.67, 0.25) (Fig. S5). Diastolic blood pressurewas not signiﬁcantly de-
creased in the prescription of medication subgroup (−0.95 mm Hg
(95% CI−2.42, 0.52)), nor in the subgroup of studies that did not pre-
scribemedications (−0.30mmHg (95% CI−1.86, 1.26) (Supplementa-
ry material online, Fig. S5). Heterogeneity was low in both analyses
(both I2 = 0%).
3.3.2.5. LDL cholesterol. Five studies [27–29,31–33] (N=1508) reported
effects on LDL cholesterol, (Fig. S7). As heterogeneity measured by the
I-square statistic was high for the LDL cholesterol analysis, a random
effects model was used. LDL was signiﬁcantly reduced in studies
that prescribed and monitored medications within programmes
(−0.31 mmol/l pooled weighted mean difference random effects
model, 95% CI−0.58,−0.04). The programmes that did not prescribe
medications did not show a signiﬁcant difference (WMD
−0.14 mmol/l (95% CI−0.36, 0.07)). The test for subgroup differences
was not signiﬁcant (p = 0.35). The I-square statistic value was high
(74%) for LDL analysis.
3.3.2.6. Sensitivity analyses. Excluding studies one by one did not signif-
icantly alter the effect of prevention and rehabilitation on all-causemor-
tality. Even after excluding themost heavily weighted study – the study
by West et al. – the effect was comparable (RR 0.97, 95% CI 0.77, 1.24).
Cardiovascular mortality became insigniﬁcant after excluding Moreno-Fig. 4.MyocardiaPalanco et al. (RR 0.85, 95% CI 0.29, 2.49). The outcome ofmyocardial in-
farction also lost signiﬁcance after omission of Moreno-Palanco et al.
(RR 0.74, 95% CI 0.55, 1.00). The outcome of cerebrovascular events
lost signiﬁcance after excluding Carrington et al. (RR 0.46, 95% CI 0.21,
1.00). Thus, effect sizes changed minimally by excluding studies one
by one except for the outcome of cardiovascular mortality (RR of 0.85
instead of 0.42).
3.3.2.7. Publication bias. The funnel plot for all-cause mortality did not
have an uneven distribution on inspection (Fig. 8) (Egger's test p =
0.3). Funnel plots for cardiovascular mortality, MI and cerebrovascular
events did not contain enough studies to be informative.
4. Discussion
4.1. Summary of main results
In this meta-analysis of contemporary randomised controlled trials
of cardiovascular prevention and rehabilitation therewas no overall im-
pact on all-cause mortality. However, comprehensive programmes ad-
dressing six or more risk factors did reduce all-cause mortality by 37%,
whereas less comprehensive programmes did not. Prescription and
monitoring of medications for blood pressure and lipids within
programmes was also associated with a signiﬁcant reduction in all-
cause mortality of 65% but those programmes not taking responsibility
for medications had no impact on survival. In the four studies reporting
cardiovascular mortality this was also signiﬁcantly reduced by 58%, as
was myocardial infarction (MI) by 30%, and for the ﬁrst time cerebro-
vascular events by 60% in patients with coronary and other atheroscle-
rotic disease. The number needed to treat for MI was 45 and 82 for
cerebrovascular events.
4.2. Comparison with other studies
The most recent Cochrane systematic review on exercise-based car-
diac rehabilitation also reports no reduction in all-cause mortality (RR
0.96, 95% CI 0.88, 1.04) based on 63 studies with 14,486 participants
and a median follow-up of 12 months. Cardiovascular mortality (RR
0.74, 95%CI 0.64, 0.86) and risk of hospital admissions (RR 0.82, 95% CI
0.70, 0.96) were both signiﬁcantly reduced. There was no signiﬁcant ef-
fect on myocardial infarction or revascularisation [16]. This contrasts
with all previous meta-analyses of cardiac rehabilitation up to 2011l infarction.
Fig. 5. Cerebrovascular events.
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diovascular mortality. The previous meta-analysis by Heran et al.,
based on 47 studies that randomised 10,794 coronary heart disease
(CHD) patients, showed that exercise-based cardiac rehabilitation was
associated with a reduction in both overall (RR 0.87, 95% CI 0.75, 0.99)
as well as cardiovascular mortality (RR 0.74, 95% CI 0.63, 0.87). Howev-
er, the risk ratio for MI was still not signiﬁcantly reduced (0.97, 95% CI
0.82, 1.15) [3].
In 2012, Janssen et al. published a meta-analysis of lifestyle
programmes from 1999 to 2009 that included 23 studies which
randomised 11,085patients [4]. The control intervention could be either
a standard cardiac rehabilitation programme or usual care. They found
that participation in a lifestyle programmewas associated with a signif-
icant reduction in total mortality of about a third, and cardiac mortality
was signiﬁcantly halved. However, ﬁndings from a more recent
Cochrane systematic review of educational interventions for patients
with CHD were somewhat different [16]. In that meta-analysis, Brown
et al. included thirteen studies that randomised 68,556 men and
women with CHD to educational intervention or usual care. All-cause
mortality and the rate ofMIwere not signiﬁcantly reduced by this inter-
vention (RR 0.79, 95%CI 0.55, 1.13 and 0.63, 95% CI 0.26, 1.48 respective-
ly). Both these meta-analyses focussed on cardiac patients while ourFig. 6. Number of risk factorstudy investigated patients with cardiac as well as other atherosclerotic
cardiovascular disease. In addition, our studywas not focussed solely on
exercise rehabilitation or on prevention but on all programmes aimed at
reducing cardiovascular risk and increasing life expectancy.
We included only recent RCTswhichmayhave resulted in important
differences with the meta-analyses that considered studies published
before 2010. For example, currently observed mortality rates following
the development of coronary disease are quite low: we found that pa-
tients in our analysis had a yearly mortality rate of b2%. Of course, ad-
vances in the management of acute coronary syndromes through
revascularisation and use of cardioprotective drugs are important fac-
tors [20], as these interventions have resulted in amuch lowermortality
rate in thewhole CHDpopulation [34]. Therefore the statistical power to
show a beneﬁt from these cardiovascular prevention and rehabilitation
programmes in terms of all-cause mortality will be reduced. Our
broader patient eligibility criteria including angina pectoris, stroke and
peripheral arterial disease could be another explanation as the beneﬁts
of such programmes may not be the same as for those patients with
myocardial infarction, although the number of such subjects was quite
small.
In addition, the “healthy adherer effect” could have caused a
favourable outcome for rehabilitation participants — especially in thes addressed (≥6 vs b6).
Fig. 7. Effect of medical risk factor management on all-cause mortality.
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patients than in earliermeta-analyses. Therefore, publication bias is less
likely to have played a role in our results compared with older meta-
analyses.
The favourable effectwe observed on cerebrovascular events has not
been reported previously. An earlier study, the GOSPEL trial, which
randomised 3241 patients with a recent MI to a lifestyle programme
or usual care, found a non-signiﬁcant reduction in non-fatal stroke
during 3-year follow-up (RR 0.84, 95% CI 0.38, 1.88) [36]. Of note, a
meta-analysis of lifestyle based rehabilitation for stroke patients report-
ed a reduction in cardiac events (OR 0.38, 95% CI 0.16, 0.88)), but not for
death or recurrent cerebrovascular events [37].
The mean age of the patients included in the studies in the current
meta-analysis varied from 56 to 70 years. Also, all studies that we
analysed included women (16–30% of the study population). ThereforeFig. 8. Funnel plot all-cause mortality.the studies included in our analysis aremore representative than previ-
ousmeta-analyses aswe included older patients andmorewomen [3,5].
4.3. Strengths and limitations
The studies we included suffered from several potential biases com-
mon to all studies in this ﬁeld of research. Loss to follow-up was the
most important one, which is a well-recognised problem in all
programmes, and could exaggerate the beneﬁts of prevention and reha-
bilitation. Other forms of bias, such as allocation bias and selective out-
come reporting, were less important but could have affected the results
as well. The low mortality in the contemporary CHD population de-
creases the power of some of our analyses, especially themortality anal-
yses. Future trials should therefore have larger patient samples andhave
a longer follow-up.
Cardiovascular mortality was presented in just four reports with a
combined total of only 32 deaths. These numbers are small and could
be biased by selective reporting. Cardiovascular mortality, MI and CVA
outcomes were all signiﬁcant outcomes of our analysis. Of note, the
four studies that analysed cardiovascular mortality also reported signif-
icantly lower all-cause mortality. The study by Moreno-Palanco et al. in
particular inﬂuenced this outcome. Two of these four studies also in-
cluded prescribing and monitoring of medications within programmes
which could have played an important role in the overall reduction in
MI and cerebrovascular events we observed.
Although highly signiﬁcant (p = 0.002), the sub-group analysis on
prescribing and monitoring of medications within programmes was
based on just three studies, two studies made up 98.3% of the total
weight, while one study – by Krebs et al. –made up only 1.7% of weight,
and a relatively small number of events. On the other hand, such amajor
effect is entirely plausible given the reduction in all cause mortality
shown by many drug trials – anti-platelet therapies, beta-blockers, ACE
inhibitors – in secondary prevention. There is also internal consistency
in our analyses in that those programmes prescribing cardioprotective
302 G. van Halewijn et al. / International Journal of Cardiology 232 (2017) 294–303medications also contributed to the reduction in all-cause mortality in
those managing six or more risk factors. This reinforces the importance
of taking a comprehensive approach beyond exercise based rehabilitation
by treating all aspects of lifestyle and associated risk factors and, in partic-
ular, prescribing and monitoring medications as an integral part of car-
diovascular prevention and rehabilitation protocols rather than
deferring this responsibility externally to other physicians.
5. Conclusions
Improving patient survival has been a hall mark of cardiac rehabili-
tation since the ﬁrst meta-analyses [38,39]. The challenge now for the
cardiac rehabilitation professions from our systematic review and
meta-analysis of contemporary trials of cardiovascular prevention and
rehabilitation programmes, and that reported for trials of exercise
based cardiac rehabilitation, both show no overall beneﬁt for total mor-
tality [16]. However, we have shown in our meta-analysis that compre-
hensive prevention and rehabilitation programmes addressing six or
more risk factors, and those prescribing and monitoring medications
within programmes, are still effective in reducing all-cause mortality.
Cardiovascular mortality, myocardial infarction and, for the ﬁrst time,
cerebrovascular eventswere also signiﬁcantly reduced. In contrast exer-
cise based cardiac rehabilitation,whilst reducing cardiovascularmortal-
ity, did not reduce myocardial infarction and stroke was not reported.
Reduction of stroke should now be considered a target for prevention
and rehabilitation programmes and included as an endpoint of trials
and meta-analyses.
The distinction between exercise based cardiac rehabilitation and
secondary prevention is artiﬁcial. As evidenced byourmeta-analysis, in-
tegrating prevention and rehabilitation to provide truly comprehensive
programmes is critical to achieving best patient outcomes; reducing
myocardial infarction, stroke, cardiovascular and all-cause mortality. A
comprehensive prevention and rehabilitation programme uses a behav-
ioural approach to address all aspects of lifestyle – smoking cessation,
diet andweightmanagement, physical activity and psychosocial factors
– together with in-programme management of all other risk factors –
blood pressure, lipids and glucose – and prescribing, monitoring and
maximising adherence with cardioprotective medications [40,41]. Yet
the reality of clinical practice as described by the EUROASPIRE surveys
is that adverse lifestyle trends in coronary patients are countering
slow improvements in risk factor management, illustrating the pressing
need for comprehensive prevention and rehabilitation [42,43]. Across
Europe only 44.8% of coronary patients are advised to participate in
any form of rehabilitation, and with an attendance rate of 81.4% only
36.5% of all eligible patients currently access any programme [12]. For
those who do so the prevalence of smoking more than a year after
hospitalisation is signiﬁcantly lower than in those who do not attend.
However, there is no impact on the prevalence of obesity and central
obesity. About half of all patients attending rehabilitation still have un-
controlled blood pressure and lipids at follow-up. Diabetes control is no
better either [12]. So the opportunity to improve patient outcomes
through a comprehensive cardiovascular prevention and rehabilitation
programme is enormous.
The challenge for exercise based cardiac rehabilitation is that all-
causemortality is no longer reduced in the era of acute revascularisation
and cardioprotective medications. However, we have shown that com-
prehensive programmes managing six or more risk factors, and those
prescribing and monitoring medications within programmes, still re-
duce all-cause and cardiovascular mortality, myocardial infarction and
stroke. There are many deﬁciencies in conventional cardiac rehabilita-
tion and secondary prevention services which need to be addressed in
order to achieve truly comprehensive care and hence the recent call to
reinvigorate our specialty [42]. All the professions involved –physicians,
nurses, dieticians, physiotherapists and physical activity specialists,
occupational therapists, psychologists, pharmacists – must face this
new challenge. We must take the opportunity to evolve cardiacrehabilitation by integrating secondary prevention and rehabilitation
to provide truly comprehensive preventive cardiology programmes
which are ﬁt for purpose in themodernmanagement of atherosclerotic
cardiovascular diseases.
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